Explore the vast range of titles available.

Guided by public health interests, the European Medicines Agency has set new standards for clinical trial data transparency by adopting a 2010 policy on access to documents and a 2014 policy on publication of clinical data for medicinal products for human use. Transparency, whether in politics, finance, or science, is a fundamental value of our society. In health care, decisions about medicines made by governments, regulators, and clinicians are, whenever possible, based on clinical trial results. We believe that patients have a right to know about the scientific basis for the approval and use of their medicines and that transparency of clinical trial data is therefore essential. Over the past 4 years, we at the European Medicines Agency (EMA) have set new standards for clinical trial data transparency by adopting two landmark policies. A 2010 policy on access to documents 1 and a . . .